Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00599391
NCT00599391UnknownPhase 1

Phase 1 Study to Examine the Use of Far Infrared Radiation for Renal Failure.

GAAD Medical Research Institute Inc.2 sites in 1 country10 target enrollmentStarted: February 1, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Sponsor
Enrollment
10
Locations
2
Primary Endpoint
Kidney Function Improvement
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Renal failure or kidney failure is a situation in which the kidneys fail to function adequately. It is divided into acute and chronic forms; either form may be due to a large number of other medical problems.

Detailed Description

There are many causes of chronic kidney disease. The most common cause is diabetes mellitus. Acute renal failure is a rapidly progressive loss of renal function, generally characterized by body fluids disturbances and electrolyte derangement.

It is believed that far infrared radiation of the central nervous system, the endocrine system and the kidneys will help in the management of renal failure and a possible cure.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •People with kidney diseases

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Kidney Function Improvement

Time Frame: 1 year

Secondary Outcomes

  • Causes of Mortality(1 year)

Investigators

Sponsor
GAAD Medical Research Institute Inc.
Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 1
VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.Kidney DiseasesHepatitis C
NCT00903773Tibotec BVBA24
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney DiseaseHealthy SubjectsPharmacokinetics of ASP8232Pharmacodynamics of ASP8232Chronic Kidney Disease (CKD)Type 2 Diabetes Mellitus (T2DM)
NCT02218099Astellas Pharma Europe B.V.55
Completed
Not Applicable
Prospective evaluation of renal function and proteinuria in chronic kidney disease patientsProteinuria
JPRN-UMIN000007371Aichi welfare agricultural cooperative association Anjo Kosei Hospital60
Withdrawn
Phase 1
Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy ParticipantsRenal Impairment
NCT05541159Novartis Pharmaceuticals
Completed
Phase 1
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal FunctionNormal Renal FunctionImpaired Renal Function
NCT02965040Astellas Pharma Europe B.V.34